MergerOct 1, 2026, 06:06 AM
Sanara MedTech Shareholders Approve Merger with MiMedx Group
AI Summary
Sanara MedTech Inc. announced that its shareholders approved the proposed merger with MiMedx Group, Inc. and its subsidiary Mustang Merger Sub, Inc. at a special meeting. The merger, which will result in Sanara becoming a wholly-owned subsidiary of MiMedx, received strong shareholder support. Additionally, shareholders approved the executive compensation related to the merger. The company also provided an update on the regulatory front, noting that the Hart-Scott-Rodino Act waiting period is expected to expire on October 15, 2026, following a voluntary withdrawal and refiling of the notification.
Key Highlights
- Sanara MedTech shareholders approved the merger with MiMedx Group, Inc. and Mustang Merger Sub, Inc.
- Proposal 1 (Merger Approval) received 6,372,989 'For' votes out of 6,411,427 total votes cast.
- Proposal 2 (Executive Compensation related to Merger) was also approved.
- The HSR Act waiting period for the merger will expire on October 15, 2026, unless extended or terminated earlier.
- MiMedx and Sanara refiled their HSR Act notification on September 15, 2026, initiating a new 30-day waiting period.
Price Impact
More from SMTI